The purpose of this study is to to assess the glycemic index and the satiating properties of different Quinoa varieties, using a Visual Analogue Scale in a sample of healthy overweight subjects.
Pilot study to evaluate the glycemic index, and the satiating effect using different Quinoa varieties in a group of healthy overweight subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
8
On the intervention day, the volunteers will consume the Quinoa Variety 1. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted: * In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected. * In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
On the intervention day, the volunteers will consume the Quinoa Variety 2. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted: * In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected. * In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
Hospital Universitairo La Paz
Madrid, Madrid, Spain
Glycemic index
The glycemic index is calculated with the incremental area under the curve of the glycemic response 7 time points ( 0 , 15 , 30, 45 , 60, 90 , 120 min) to 50 g intake carbohydrate food test food and reference
Time frame: 0, 15, 30, 45, 60, 90, 120 min
Glucose metabolism related parameters
glucose and insulin assessed in 7 point curves
Time frame: day 1, 8, 15, 22, 29
satiety hunger assessment (visual analogue scale)
visual analogue scale to assessment satiety and hunger will be picked up in 9 time points to calculate the area under the curve to get a score
Time frame: just before taking the product, just after taking the product, 30, 60 , 90, 120, 180, 240 min and 260 min after taking the product)
Weight
Weight
Time frame: day 1, 8, 15, 22, 29
Adverse effects
symptoms of gastrointestinal intolerance (nausea, diarrhea, bloating or other gastrointestinal disorder
Time frame: day 1, 8, 15, 22, 29
Blood hormonal markers
ghrelin, GLP-1 (glucagon-like peptide) and peptide YY
Time frame: just before taking the product, 15, 30, 45, 60, 90 and 120 min after consuming the product
height
Time frame: day 1, 8, 15, 22, 29
waist circumference
Time frame: day 1, 8, 15, 22, 29
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
On the intervention day, the volunteers will consume the Quinoa Variety 3. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted: * In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected. * In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
On the intervention day, the volunteers will consume the Quinoa Variety 4. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted: * In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected. * In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
On the intervention day, the volunteers will consume the control product. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted: * In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected. * In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
BMI
body mass index
Time frame: day 1, 8, 15, 22, 29